Oxford, UK and Regensburg, Germany, January 29, 2013 / B3C newswire / - Oxford Immunotec, a medical diagnostic company developing tests in the fields of infectious and immunological disease and Lophius Biosciences, a leader in the field of novel T-cell based diagnostic test systems, announced today that the companies have signed agreements under which both companies will have access to certain intellectual property from the other party. Oxford Immunotec will be able to develop and commercialize novel T-cell based assays using Lophius´ proprietary UREA technology in certain territories. Lophius Biosciences will be able to develop and commercialize novel T-cell based assays under a license to Oxford Immunotec’s proprietary T-SPOT® technology. Financial terms were not disclosed.
Dr. Peter Wrighton-Smith, Chief Executive Officer, Oxford Immunotec commented: “We believe that Lophius’s UREA technology has distinct advantages over conventional methods of designing and producing antigens for T-cell based diagnostic test systems. We are looking forward to combining Lophius’s technology with our own, to develop and launch innovative new assays for infectious and immunological disease”.
“We are very pleased with this partnership with Oxford Immunotec, a leading company in the development of T-cell based assays, which provides us access to the T-SPOT® technology. This cooperation also confirms the commercial potential of our proprietary UREA technology platform which led to recent successful development of two CE-marked tests, namely T-Track® CMV and T-Track® EBV.” said Dr. Michael Lutz, Managing Director of Lophius Biosciences.
About Lophius Biosciences
Lophius Biosciences GmbH develops and markets innovative T-cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.
About Oxford Immunotec
Oxford Immunotec Ltd., a global immunology-focused diagnostic company, is headquartered near Oxford, UK; with US operations in Marlborough, MA and Memphis, TN and Japanese operations in Tokyo. The company is developing novel tests in the fields of infectious and immunological disease based primarily on its patented T-SPOT® technology, the first FDA-approved method for directly quantifying antigen-specific T cells.
T-SPOT technology is a simple and extremely accurate method of studying a person’s cellular immune response and, as such, provides a unique methodology to diagnose and monitor diseases driven by a T cell response.
Contacts
Lophius Biosciences GmbH
Josef-Engert-Str. 13
93053 Regensburg, Germany
Phone: +49 941 6309 1972
Email: info@lophius.de
www.lophius.de
Oxford Immunotec, Ltd
94C Milton Park
Abingdon
Oxfordshire OX14 4RY, UK
Phone: +44 1235 442780
Email: info@oxfordimmunotec.com
www.oxfordimmunotec.com
